CENTOGENE receives FDA Emergency Use Authorization for SARS-CoV-2 RT-PCR assay for individuals without symptoms or other reasons to suspect COVID-19

CENTOGENE, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, has announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for ‘CentoSure’, the company's latest SARS-CoV-2 RT-PCR test. The EUA permits the usage of this test for individuals without any symptoms or suspicion of COVID-19 – supporting widespread testing for the global population.

Prof. Arndt Rolfs, CEO of CENTOGENE, said, “This emergency use authorization by the FDA is an extremely important further step to prevent a further spread of COVID-19, specifically in countries that have been heavily impacted, like the U.S. Our experiences to date show that infected people do not always develop symptoms or are unknowingly spreading the virus days before they start to feel sick. Broad preventative testing is the best way to detect SARS-CoV-2 infections and successfully prevent the next wave of infections to effectively fight the COVID-19 pandemic. We are proud to be able to support the global community by providing the best possible molecular diagnostic test available.”

“We are excited to have been granted this emergency use authorization by the FDA – further validating our commitment to quality, precision, and reliability amid this global fight against the novel coronavirus,” added Dr. Florian Vogel, Senior Vice President Clinical Lab Operations of CENTOGENE.

About CENTOGENE’s CentoSure SARS-CoV-2 RT-PCR Assay

CENTOGENE’S CentoSure SARS-CoV-2 RT-PCR assay is a real-time test based on the reverse transcription polymerase chain reaction (RT-PCR) for the qualitative detection of SARS-CoV-2, the underlying virus causing COVID-19. This is a multiplex test for two viral targets and a human gene, as extraction control for every sample.

The test has also been validated in CENTOGENE's CAP / CLIA / ISO-certified analytical laboratory and has received Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) for use by authorized laboratories. It is intended to be used with samples of the upper respiratory tract (oropharyngeal swabs) collected from individuals without symptoms or other reasons to suspect COVID-19. Once a sample has been collected, it is brought to a CENTOGENE laboratory for testing. Test results are delivered via CENTOGENE’s Corona Test Portal – a secure digital platform following stringent data privacy measures and the Health Insurance Portability and Accountability Act (HIPAA).

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>